Saumil Gandhi | MD Anderson Cancer Center

Dr. Saumil Gandhi, MD

Claim this profile

M D Anderson Cancer Center

Studies Lung Cancer
Studies Non-Small Cell Lung Cancer
8 reported clinical trials
18 drugs studied

Area of expertise

1

Lung Cancer

Saumil Gandhi, MD has run 5 trials for Lung Cancer. Some of their research focus areas include:

Stage IV
EGFR positive
Stage III
2

Non-Small Cell Lung Cancer

Saumil Gandhi, MD has run 3 trials for Non-Small Cell Lung Cancer. Some of their research focus areas include:

Stage IV
EGFR positive
Stage III

Affiliated Hospitals

Image of trial facility.

M D Anderson Cancer Center

Image of trial facility.

MD Anderson League City

Clinical Trials Saumil Gandhi, MD is currently running

Image of trial facility.

Proton Therapy vs Photon Radiation

for Esophageal Cancer

This trial studies how well proton beam radiation therapy compared with intensity modulated photon radiotherapy works in treating patients with stage I-IVA esophageal cancer. Proton beam radiation therapy uses a beam of protons (rather than x-rays) to send radiation inside the body to the tumor without damaging much of the healthy tissue around it. Intensity modulated photon radiotherapy uses high-energy x-rays to deliver radiation directly to the tumor without damaging much of the healthy tissue around it. It is not yet known whether proton beam therapy or intensity modulated photon radiotherapy will work better in treating patients with esophageal cancer.

Recruiting

2 awards

Phase 3

1 criteria

Image of trial facility.

NBTXR3 + Radiation and Immunotherapy

for Metastatic Lung Cancer

This phase I/II trial studies the side effects and possible benefits of NBTXR3, radiation therapy, Anti PD-1 / PD-L1 in treating patients with solid tumor that has spread to the lung (lung metastases) and/or liver (liver metastases). NBTXR3 may help make tumor cells more sensitive to the radiation therapy. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Immunotherapy with Anti PD-1 / PD-L1 monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving NBTXR3, radiation therapy, Anti PD-1 / PD-L1 may help to control the disease.

Recruiting

1 award

Phase 1 & 2

13 criteria

More about Saumil Gandhi, MD

Clinical Trial Related

6 years of experience running clinical trials · Led 8 trials as a Principal Investigator · 3 Active Clinical Trials

Treatments Saumil Gandhi, MD has experience with

  • Radiation Therapy
  • NBTXR3
  • Pemetrexed Disodium
  • Osimertinib
  • Therapeutic Conventional Surgery
  • Stereotactic MRI-guided Adaptive Radiotherapy-SMART

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does Saumil Gandhi, MD specialize in?

Is Saumil Gandhi, MD currently recruiting for clinical trials?

Are there any treatments that Saumil Gandhi, MD has studied deeply?

What is the best way to schedule an appointment with Saumil Gandhi, MD?

What is the office address of Saumil Gandhi, MD?

Is there any support for travel costs?